Insta
COVID-19: Govt To Discontinue Central Allocation Of Remdesivir To States As Supply Of Antiviral Drug Far Exceeds Demand
Swarajya Staff
May 30, 2021, 10:07 AM | Updated 10:07 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
The government on Saturday (29 May) said that it has decided to discontinue the central allocation of antiviral Remdesivir, which is being used in treatment of Covid-19 patients across the country, to the states as the supply of the drug in the nation has far exceeded the demand.
The production of Remdesivir is ramped up ten times from 33,000 vials per day on 11 April to 3,50,000 vials per day, informed Minister of State for Chemicals and Fertilizers Mansukh Mandaviya on Saturday (29 may).
He further informed that the government has also increased the number of plants producing Remdesivir from 20 to 60 within a month.
"Now the country has enough Remdesivir as the supply is much more than the demand. So we have decided to DISCONTINUE the Central Allocation of Remdesivir to states," Mandaviya said in a tweet.
The Centre has also decided to procure 50 lakh vials of Remdesivir to maintain it as a strategic stock for the emergency requirement, he added.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.